Valuation : Vectus Biosystems Limited

Market Cap 9.25M 6.63M 5.71M 5.39M 4.9M 9.17M 632M 64.13M 24.68M 322M 24.88M 24.33M 1.02B P/E 2025
-1.2x
P/E 2026 4.45x
Enterprise Value 6.28M 4.5M 3.87M 3.66M 3.33M 6.22M 429M 43.55M 16.76M 219M 16.89M 16.52M 695M EV / Sales 2025
4.35x
EV / Sales 2026 1.7x
Free-Float
57.14%
Yield 2025 *
-
Yield 2026 -
1 day-3.23%
1 week-18.92%
Current month-18.92%
1 month-6.25%
3 months+20.00%
6 months+20.00%
Current year-16.67%
1 week 0.15
Extreme 0.15
0.18
1 month 0.15
Extreme 0.15
0.19
Current year 0.09
Extreme 0.09
0.22
1 year 0.05
Extreme 0.053
0.46
3 years 0.04
Extreme 0.037
0.46
5 years 0.04
Extreme 0.037
2.2
10 years 0.04
Extreme 0.037
2.2
Manager TitleAgeSince
Chief Executive Officer - 2026-05-06
Corporate Secretary - 2015-07-08
Director TitleAgeSince
Director/Board Member - 2005-12-11
Chairman - 2018-08-30
Director/Board Member - 2024-12-19
Change 5-day change 1-year change 3-year change Capi.($)
-3.23%-18.92%+105.48%-62.50% 6.9M
-0.56%-8.30%-5.88%+10.58% 46.38B
-2.08%-2.81%+396.70%+533.09% 44.51B
+0.12%-2.48%+35.68%+20.50% 42.3B
-2.62%-5.52%-2.66%+77.44% 39.91B
-1.26%-2.95%+12.00%+40.55% 32.79B
+0.16%-2.27% - - 17.13B
-0.54%-1.66%+20.09%+115.10% 16.36B
-0.03%-2.56%+10.88%+30.90% 14.31B
-1.92%-6.43%+73.47%+36.68% 13.29B
Average -1.20%-4.39%+71.75%+89.15% 26.7B
Weighted average by Cap. -1.09%-3.25%+82.62%+129.35%

Financials

2025 2026
Net sales 478K 342K 295K 278K 253K 474K 32.67M 3.31M 1.28M 16.65M 1.29M 1.26M 52.92M 2.77M 1.98M 1.71M 1.61M 1.47M 2.74M 189M 19.18M 7.38M 96.32M 7.44M 7.28M 306M
Net income -1.78M -1.27M -1.1M -1.03M -941K -1.76M -121M -12.32M -4.74M -61.87M -4.78M -4.67M -197M 1.56M 1.12M 961K 908K 825K 1.54M 107M 10.8M 4.16M 54.26M 4.19M 4.1M 173M
Net Debt -50.99K -36.51K -31.44K -29.69K -27K -50.51K -3.48M -353K -136K -1.77M -137K -134K -5.64M -2.97M -2.13M -1.83M -1.73M -1.57M -2.94M -203M -20.58M -7.92M -103M -7.98M -7.81M -329M
Logo Vectus Biosystems Limited
Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.
Employees
-
Date Price Change Volume
26-09-10 A$0.1500 -3.23% 62,810
26-09-09 A$0.1550 -6.06% 13,300
26-09-07 A$0.1650 -10.81% 15,118
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!